|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, cell cycle inhibition was identified as a common principle of TRAIL sensitization in melanoma cells.
|
31083589 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A TRAIL-Delivered Lipoprotein-Bioinspired Nanovector Engineering Stem Cell-Based Platform for Inhibition of Lung Metastasis of Melanoma.
|
31244937 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pro-inflammatory response to melanoma by nF κB and STAT3 pathways makes the cancer cells resist TRAIL-induced apoptosis.
|
30157799 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report that Ca2+ protects malignant melanoma (MM) and osteosarcoma (OS) cells from tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) cytotoxicity.
|
28560396 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, we showed that up-regulation of this gene by the histone deacetylase inhibitor MS-275 was responsible for sensitization to TRAIL-induced apoptosis through c-FLIP repression in melanoma.
|
27620505 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results showed that DNA fragments from apoptotic MDA triggered hMSCs to increase further TRAIL expression in an absent in melanoma 2 (AIM2)-dependent manner, and thus higher TRAIL-expressing hMSCs stimulated with synthetic DNA, poly(deoxyadenylic-deoxythymidylic) acid [poly(dA:dT)], more effectively suppressed tumor progression in vivo.
|
26227206 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We combined treatment with an aurora kinase A inhibitor, MLN8237, with agents that activate death receptors (Apo2L/TRAIL or death receptor 5 agonists) and monitored the ability of this treatment to induce tumor apoptosis and melanoma tumor regression using human cell lines and patient-derived xenograft (PDX) mouse models.
|
26152738 |
2015 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, experiments in both hepatocellular carcinoma and melanoma-bearing mice demonstrated that the genetically engineered rNDV-IL-2-TRAIL exhibited prolonged animals' survival compared with rNDV, rNDV-IL-2, and rNDV-TRAIL.
|
24971746 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, recombinant human TRAIL and drozitumab (anti-DR5 agonistic mAb) were used to explicitly verify the contribution of the DR5/TRAIL pathway in killing melanomas.
|
24639349 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies describe a novel regulation of TRAIL sensitivity in melanoma by Wnt/β-catenin signaling, and suggest that strategies to enhance Wnt/β-catenin signaling in combination with TRAIL agonists warrant further investigation.
|
23869245 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that IL-27 inhibits in vitro tumor growth of human melanomas and greatly enhances the expression of TNF-related apoptosis inducing ligand (TRAIL) in a dose-dependent manner.
|
24155891 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma.
|
24211571 |
2013 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apollon modulation and melanoma apoptosis were evaluated by Western blot and/or flow cytometry in response to cytotoxic drugs, mitogen-activated protein/extracellular signal-regulated kinase (MEK)-, BRAF(V600E)-, and mTOR-specific inhibitors, TRAIL and anti-HLA class II monoclonal antibodies (mAb).
|
22553342 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the importance of the IAPs in the resistance to the commonly used chemotherapeutic agent dacarbazine (DTIC) and the apoptosis inducer TRAIL (TNF-related apoptosis inducing ligand) in malignant melanoma.
|
21508672 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we present evidence that the recently described indirubin derivative 8-Rha-β enhances melanoma cell sensitivity for death ligands and overcomes resistance to TRAIL and CD95 agonists.
|
20858462 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism of antimelanoma action comprised dual drug activity-induction of apoptotic cell death and acquisition of melanoma cell responsiveness to TRAIL.
|
21506111 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As an alternative approach, pretreatment of melanoma cells with statin at decreased doses (5-20 μM) dramatically enhanced TRAIL-induced apoptosis, due to suppression of the NF-κB and STAT3-transcriptional targets (including COX-2) and downregulation of cFLIP-L (a caspase-8 inhibitor) protein levels.
|
21910007 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results show that activation of caspase-4 contributes to TRAIL-induced apoptosis and is associated with induction of ER stress by TRAIL in melanoma cells, and may have important implications for improving therapeutic efficacies of TRAIL in melanoma.
|
20514521 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.
|
21092273 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma.
|
20417200 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results show that nutlin-3 may be a useful agent in combination with TRAIL and, importantly, uncover a novel regulatory effect of p53 on the expression of Mcl-1 in melanoma cells on treatment with nutlin-3, which may antagonize the therapeutic efficacy of other chemotherapeutic drugs in addition to docetaxel in melanoma.
|
21159614 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased expression of genes, silenced by methylation of their promoters, could have relevance for increasing effects of not only interferons (IFNs) but also APO2L/TRAIL, cytotoxics and immunotherapeutics for melanoma and other malignancies.
|
17689283 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that resveratrol, in combination with TRAIL, may have a significant efficacy in the treatment of human melanomas.
|
18222423 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TRAIL-resistant prostate carcinoma PC-3 and melanoma M202 cell lines were examined.
|
17911631 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The system uses S100 to define pixels as melanoma (tumor mask) within the array spot and measures intensity of TRAIL-receptor expression using Cy5-conjugated antibodies within the mask.
|
16778114 |
2006 |